Results 1 to 10 of about 768 (125)

Sulbactam–Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii: A Narrative Review [PDF]

Antibiotics
The increasing prevalence of infections caused by multidrug-resistant (MDR) Gram-negative bacteria represents a major global public health challenge.
Szymon Viscardi, Patrycja Lipska, Piotr Niezgódka, Anna Duda-Madej   +3 more
doaj   +3 more sources

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex [PDF]

Pathogens
Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease
Francesco Nappi
doaj   +3 more sources

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease [PDF]

Antimicrobial Agents and Chemotherapy
The guideline-based therapy achieves sputum culture conversion rates in 20%–34% of patients with Mycobacterium abscessus (MAB) lung disease (LD). Double-β-lactam combinations have been proposed to improve cure based on time-kill curves.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D. Boorgula, Mary C. Long, Brian Robbins, Pamela J. McShane, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +4 more sources

Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam–Durlobactam in a Preterm Neonate: A Case Report [PDF]

Infectious Disease Reports
Background: Ventilator-associated pneumonia (VAP) is a leading cause of nosocomial infections in neonatal intensive care units (NICUs) and is associated with significant morbidity, mortality, and prolonged hospitalization, particularly in preterm ...
Suzana Zivojinovic, Tijana Prodanovic, Nikola Prodanovic, Rasa Medovic, Milica Cekerevac, Dragana Savic, Bojana Markovic, Slobodan Jankovic   +7 more
doaj   +3 more sources

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece [PDF]

Frontiers in Cellular and Infection Microbiology, 2022
BackgroundAcinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Maria Siopi, Spyros Pournaras
exaly   +6 more sources

Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data [PDF]

Antimicrobial Agents and Chemotherapy
ABSTRACT Sulbactam–durlobactam is a β-lactam/β-lactamase inhibitor combination approved in the United States for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus in adults.
John O'Donnell, Michael Trang, Christopher Rubino   +2 more
exaly   +4 more sources

Resistance of Acinetobacter baumannii Complex Clinical Isolates to Sulbactam–Durlobactam: A Systematic Review of Data from In Vitro Studies [PDF]

Pathogens
Introduction: Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam–durlobactam, has been developed.
Matthew E. Falagas, Laura T. Romanos, Dimitrios Ragias, Charalampos Filippou   +3 more
doaj   +4 more sources

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus [PDF]

Microbiology Spectrum
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase ...
Avneesh Shrivastava, Gunavanthi D. Boorgula, Sanjay Singh, Danaleigh Stiles, Pamela J. McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +4 more sources

Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report [PDF]

Frontiers in Pharmacology
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Ju Gao, Xia Guo
exaly   +4 more sources

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review

Antibiotics, 2022
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a
Luigi Principe, Stefano Di Bella, Jacopo Conti, Mariagrazia Perilli, Alessandra Piccirilli, Cristina Mussini, Giuliana Decorti   +6 more
doaj   +3 more sources